Stonepine Capital Management, Llc Portfolio Stock Holdings
According to the SEC 13F filed on August 17, 2026, Stonepine Capital Management, Llc disclosed 71 stock positions valued at approximately $131.36M as of quarter-end June 30, 2026. The largest holdings include VERASTEM INC, EVOLUS INC, and TENAX THERAPEUTICS INC.
- Report Period
- June 30, 2026
- No. of Stocks
- 71
- Portfolio Value
- $131.36M
Holdings by Sector
Stonepine Capital Management, Llc Portfolio Holdings in Q2 2026
| Company | Symbol | Sector | Portfolio % | Shares | Change (Shares) | Change % | Value |
|---|---|---|---|---|---|---|---|
| VERASTEM INC | VSTM | Healthcare | 9.74% | 3,349,627 | +47,327 | +1.43% | $12,795,575 |
| EVOLUS INC | EOLS | Healthcare | 8.40% | 1,590,162 | -168,929 | -9.60% | $11,035,724 |
| TENAX THERAPEUTICS INC | TENX | Healthcare | 7.31% | 660,000 | -315,200 | -32.32% | $9,603,000 |
| NEKTAR THERAPEUTICS | NKTR | Healthcare | 6.41% | 120,654 | +35,654 | +41.95% | $8,422,856 |
| ADMA BIOLOGICS INC | ADMA | Healthcare | 4.72% | 740,000 | - | - | $6,193,800 |
| CAMP4 THERAPEUTICS CORP | CAMP | Healthcare | 4.62% | 1,389,622 | - | - | $6,072,648 |
| ELOXX PHARMACEUTICALS INC | ELOX | Healthcare | 4.20% | 397,160 | +397,160 | +100.00% | $5,512,581 |
| KAZIA THERAPEUTICS LTD | KZIA | Healthcare | 3.70% | 345,179 | - | - | $4,860,120 |
| INDIVIOR PHARMACEUTICALS INC | INDV | Healthcare | 3.12% | 100,000 | - | - | $4,103,000 |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | Healthcare | 3.03% | 425,000 | +41,538 | +10.83% | $3,986,500 |
| SATELLOS BIOSCIENCE INC | MSLE | Healthcare | 2.83% | 491,624 | +391,624 | +391.62% | $3,723,291 |
| ZEVRA THERAPEUTICS INC | ZVRA | Healthcare | 2.82% | 258,701 | -221,299 | -46.10% | $3,709,772 |
| ABEONA THERAPEUTICS INC | ABEO | Healthcare | 2.62% | 557,284 | -189,303 | -25.36% | $3,444,015 |
| EDESA BIOTECH INC | EDSA | Healthcare | 2.43% | 456,439 | +426,439 | +1421.46% | $3,190,807 |
| CABALETTA BIO INC | CABA | Healthcare | 2.17% | 917,100 | +867,100 | +1734.20% | $2,852,181 |
| AN2 THERAPEUTICS INC | ANTX | Healthcare | 2.03% | 551,692 | -162,153 | -22.72% | $2,670,190 |
| XILIO THERAPEUTICS INC | XLO | Healthcare | 1.65% | 225,994 | +161,832 | +252.22% | $2,165,023 |
| ADICET BIO INC | ACET | Healthcare | 1.61% | 245,518 | +23,563 | +10.62% | $2,121,276 |
| TELA BIO INC | TELA | Healthcare | 1.52% | 2,662,427 | +45,175 | +1.73% | $1,996,820 |
| AYTU BIOPHARMA INC | AYTU | Healthcare | 1.49% | 912,921 | +120,632 | +15.23% | $1,962,780 |
| CURIS INC | CRIS | Healthcare | 1.32% | 3,312,185 | -414,221 | -11.12% | $1,729,292 |
| SPRUCE BIOSCIENCES INC | SPRB | Healthcare | 1.18% | 28,795 | +9,053 | +45.86% | $1,554,930 |
| OKYO PHARMA LTD | OKYO | Healthcare | 0.99% | 862,996 | +12,996 | +1.53% | $1,294,494 |
| PASITHEA THERAPEUTICS CORP | KTTA | Healthcare | 0.86% | 2,201,468 | +1,370,167 | +164.82% | $1,134,637 |
| SOL-GEL TECHNOLOGIES LTD | SLGL | Healthcare | 0.82% | 14,469 | -13,309 | -47.91% | $1,072,732 |
| PULMONX CORP | LUNG | Healthcare | 0.81% | 815,436 | +47,148 | +6.14% | $1,060,067 |
| X4 PHARMACEUTICALS INC | XFOR | Healthcare | 0.80% | 224,989 | -110,320 | -32.90% | $1,050,699 |
| IN8BIO INC | INAB | Healthcare | 0.75% | 695,287 | +31,875 | +4.80% | $980,355 |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | Healthcare | 0.74% | 50,000 | +50,000 | +100.00% | $973,500 |
| QUOIN PHARMACEUTICALS LTD | QNRX | Healthcare | 0.74% | 199,486 | +146,026 | +273.15% | $965,512 |
Showing 30 of 71 holdings in the latest reporting period.
Stonepine Capital Management, Llc Options Holdings in Q2 2026
| Quarter | Symbol | Company | Option | Contracts | Notional Value |
|---|---|---|---|---|---|
| Q2 2026 | ADMA | ADMA Biologics Inc | CALL | 650,000 | $7,950,000 |
| Q2 2026 | INSM | Insmed Incorporated | CALL | 40,000 | $5,600,000 |
| Q2 2026 | RARE | Ultragenyx Pharmaceutical Inc. | CALL | 200,000 | $5,500,000 |
| Q2 2026 | MDT | Medtronic plc. | CALL | 50,000 | $4,375,000 |
| Q2 2026 | ABT | Abbott Laboratories | CALL | 40,000 | $3,800,000 |
| Q2 2026 | BSX | Boston Scientific Corporation | CALL | 50,000 | $3,250,000 |
| Q2 2026 | EOLS | Evolus, Inc. Common Stock | CALL | 420,000 | $3,150,000 |
| Q2 2026 | BMRN | BioMarin Pharmaceutical Inc. | CALL | 50,000 | $3,125,000 |
| Q2 2026 | XERS | Xeris Biopharma Holdings, Inc. | CALL | 280,000 | $2,100,000 |
| Q2 2026 | HRTX | Heron Therapeutics, Inc. | CALL | 1,000,000 | $1,500,000 |
| Q2 2026 | SIBN | SI-BONE, Inc. | CALL | 100,000 | $1,500,000 |
| Q2 2026 | NMRA | Neumora Therapeutics, Inc. | CALL | 500,000 | $1,250,000 |
| Q2 2026 | ARDX | Ardelyx, Inc. | CALL | 150,000 | $1,050,000 |
| Q2 2026 | DCTH | Delcath Systems, Inc. | CALL | 100,000 | $1,000,000 |
| Q2 2026 | MNKD | MannKind Corporation | CALL | 250,000 | $750,000 |
Showing 15 of 15 options positions in the latest reporting period.
Notional value represents the total exposure of the options position.